The efficacy of DASH combined with time-restricted feeding (16/8) on metabolic associated fatty liver disease management: a randomized controlled trial
Abstract Recent studies have utilized time-restricted feeding (16/8) (TRF) and dietary approaches to stop hypertension separately to manage metabolic-associated fatty liver disease (MAFLD); however, the effectiveness of combining these two approaches has not been investigated. The objective of this...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-88393-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850238010011942912 |
|---|---|
| author | Maryam Nilghaz Amir Sadeghi Glareh Koochakpoor Hossein Poustchi Navideh Khodadadi Behnaz Narimani Maryam Ghods Mahshad Shafiee Mohammad Reza Shahparvari Azita Hekmatdoost |
| author_facet | Maryam Nilghaz Amir Sadeghi Glareh Koochakpoor Hossein Poustchi Navideh Khodadadi Behnaz Narimani Maryam Ghods Mahshad Shafiee Mohammad Reza Shahparvari Azita Hekmatdoost |
| author_sort | Maryam Nilghaz |
| collection | DOAJ |
| description | Abstract Recent studies have utilized time-restricted feeding (16/8) (TRF) and dietary approaches to stop hypertension separately to manage metabolic-associated fatty liver disease (MAFLD); however, the effectiveness of combining these two approaches has not been investigated. The objective of this study was to examine the impact of TRF in conjunction with a DASH diet on various factors related to MAFLD. A 12-week randomized controlled trial was conducted to assess the impact of TRF (16/8), along with a DASH diet, compared with a control diet based on standard meal distribution, in patients with MAFLD. An investigation was conducted to examine alterations in anthropometric indices, as well as liver parameters, serum metabolic indices, and an inflammatory marker. The TRF plus DASH diet reduced body mass index (p = 0.03), abdominal circumference (p = 0.005), controlled attenuation parameter (CAP) (p < 0.001), alanine aminotransferase (p = 0.039), and aspartate aminotransferase (0.047) compared to the control group. The levels of insulin and homeostasis model assessment of insulin resistance reduced in both groups significantly (P < 0.05). In MAFLD patients, TRF (16/8) in combination with a DASH diet is superior to a low-calorie diet in promoting obesity indices, and hepatic steatosis and fibrosis. Further long-term investigations are needed to draw definitive conclusions. |
| format | Article |
| id | doaj-art-ef643cf3a76b4391ad6bca38359afa57 |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-ef643cf3a76b4391ad6bca38359afa572025-08-20T02:01:35ZengNature PortfolioScientific Reports2045-23222025-02-0115111310.1038/s41598-025-88393-7The efficacy of DASH combined with time-restricted feeding (16/8) on metabolic associated fatty liver disease management: a randomized controlled trialMaryam Nilghaz0Amir Sadeghi1Glareh Koochakpoor2Hossein Poustchi3Navideh Khodadadi4Behnaz Narimani5Maryam Ghods6Mahshad Shafiee7Mohammad Reza Shahparvari8Azita Hekmatdoost9Department of Clinical Nutrition, School of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical SciencesGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical SciencesMaragheh University of Medical SciencesDigestive Disease Research Institute, Tehran University of Medical SciencesDepartment of Clinical Nutrition, School of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical SciencesDepartment of Clinical Nutrition, School of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical SciencesDepartment of Clinical Nutrition, School of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical SciencesDepartment of Clinical Nutrition, School of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical SciencesDepartment of Clinical Nutrition, School of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical SciencesDepartment of Clinical Nutrition, School of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical SciencesAbstract Recent studies have utilized time-restricted feeding (16/8) (TRF) and dietary approaches to stop hypertension separately to manage metabolic-associated fatty liver disease (MAFLD); however, the effectiveness of combining these two approaches has not been investigated. The objective of this study was to examine the impact of TRF in conjunction with a DASH diet on various factors related to MAFLD. A 12-week randomized controlled trial was conducted to assess the impact of TRF (16/8), along with a DASH diet, compared with a control diet based on standard meal distribution, in patients with MAFLD. An investigation was conducted to examine alterations in anthropometric indices, as well as liver parameters, serum metabolic indices, and an inflammatory marker. The TRF plus DASH diet reduced body mass index (p = 0.03), abdominal circumference (p = 0.005), controlled attenuation parameter (CAP) (p < 0.001), alanine aminotransferase (p = 0.039), and aspartate aminotransferase (0.047) compared to the control group. The levels of insulin and homeostasis model assessment of insulin resistance reduced in both groups significantly (P < 0.05). In MAFLD patients, TRF (16/8) in combination with a DASH diet is superior to a low-calorie diet in promoting obesity indices, and hepatic steatosis and fibrosis. Further long-term investigations are needed to draw definitive conclusions.https://doi.org/10.1038/s41598-025-88393-7DASHTRFDietMAFLDNAFLD |
| spellingShingle | Maryam Nilghaz Amir Sadeghi Glareh Koochakpoor Hossein Poustchi Navideh Khodadadi Behnaz Narimani Maryam Ghods Mahshad Shafiee Mohammad Reza Shahparvari Azita Hekmatdoost The efficacy of DASH combined with time-restricted feeding (16/8) on metabolic associated fatty liver disease management: a randomized controlled trial Scientific Reports DASH TRF Diet MAFLD NAFLD |
| title | The efficacy of DASH combined with time-restricted feeding (16/8) on metabolic associated fatty liver disease management: a randomized controlled trial |
| title_full | The efficacy of DASH combined with time-restricted feeding (16/8) on metabolic associated fatty liver disease management: a randomized controlled trial |
| title_fullStr | The efficacy of DASH combined with time-restricted feeding (16/8) on metabolic associated fatty liver disease management: a randomized controlled trial |
| title_full_unstemmed | The efficacy of DASH combined with time-restricted feeding (16/8) on metabolic associated fatty liver disease management: a randomized controlled trial |
| title_short | The efficacy of DASH combined with time-restricted feeding (16/8) on metabolic associated fatty liver disease management: a randomized controlled trial |
| title_sort | efficacy of dash combined with time restricted feeding 16 8 on metabolic associated fatty liver disease management a randomized controlled trial |
| topic | DASH TRF Diet MAFLD NAFLD |
| url | https://doi.org/10.1038/s41598-025-88393-7 |
| work_keys_str_mv | AT maryamnilghaz theefficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT amirsadeghi theefficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT glarehkoochakpoor theefficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT hosseinpoustchi theefficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT navidehkhodadadi theefficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT behnaznarimani theefficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT maryamghods theefficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT mahshadshafiee theefficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT mohammadrezashahparvari theefficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT azitahekmatdoost theefficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT maryamnilghaz efficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT amirsadeghi efficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT glarehkoochakpoor efficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT hosseinpoustchi efficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT navidehkhodadadi efficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT behnaznarimani efficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT maryamghods efficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT mahshadshafiee efficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT mohammadrezashahparvari efficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial AT azitahekmatdoost efficacyofdashcombinedwithtimerestrictedfeeding168onmetabolicassociatedfattyliverdiseasemanagementarandomizedcontrolledtrial |